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Antifibrinolytic Agents in Traumatic Hemorrhage: A Large
Scale Randomized Controlled Trial Is Needed
For people 5 to 45 years old trauma is,
after HIV/AIDS, the second cause of death. Each
year, worldwide, over three million people die as
a result of trauma, many after reaching hospital (1).
Among trauma patients who do survive long
enough to reach hospital, exsanguination is a com-
mon cause of death, accounting for nearly half of
in-hospital trauma deaths (2). Central nervous sys-
tem injury and multi-organ failure account for
most of the remainder, both of which can be exac-
erbated by severe bleeding (3).
The haemostatic system helps to main-
tain the integrity of the circulatory system after se-
vere vascular injury, whether traumatic or surgical
in origin (4). Major surgery and trauma trigger sim-
ilar haemostatic responses and any consequent
massive blood loss presents an extreme challenge
to the coagulation system. Part of the response to
surgery and trauma, in any patient, is stimulation
of clot breakdown (fibrinolysis) which may be-
come pathological (hyper-fibrinolysis) in some (4).
Antifibrinolytic agents have been shown to reduce
blood loss in patients with both normal and exag-
gerated fibrinolytic responses to surgery and do so
without apparently increasing the risk of post-op-
erative complications, most notably there is no
increased risk of venous thromboembolism (5).
Systemic antifibrinolytic agents are wi-
dely used in major surgery to prevent fibrinolysis
and thus reduce surgical blood loss. A recent sys-
tematic review (6) of randomized controlled trials
of antifibrinolytic agents (mainly aprotinin or tran-
examic acid) in elective surgical patients identified
89 trials including 8,580 randomized patients (74
trials in cardiac, eight in orthopedic, four in liver,
and three in vascular surgery). The results showed
that these treatments reduced the numbers need-
ing transfusion by one third, reduced the volume
needed per transfusion by one unit, and halved the
need for further surgery to control bleeding. These
differences were all highly statistically significant.
There was also a statistically non-significant reduc-
tion in the risk of death (RR=0.85, 95%CI 0.63 to
1.14) in the antifibrinolytic treated group.
Because the haemostatic abnormalities
that occur after injury are similar to those after sur-
gery, it is possible that antifibrinolytic agents
might also reduce blood loss, the need for transfu-
sion and mortality following trauma. However, to
date there has been only one small randomized
controlled trial (70 randomized patients, drug ver-
sus placebo: 0 versus 3 deaths) of the effect of
antifibrinolytic agents in major trauma (7). As a re-
sult, there is insufficient evidence to either support
or refute a clinically important treatment effect.
Systemic antifibrinolytic agents have been used in
the management of eye injuries where there is
some evidence that they reduce the rate of second-
ary hemorrhage (8).
A simple and widely practicable treat-
ment that reduces blood loss following trauma
might prevent thousands of premature trauma
deaths each year and secondly could reduce expo-
sure to the risks of blood transfusion. Blood is a
scarce and expensive resource and major con-
cerns remain about the risk of transfusion-transmit-
ted infection. Trauma is common in parts of the
world where the safety of blood transfusion is not
assured. A recent study in Uganda estimated the
population-attributable fraction of HIV acquisition
as a result of blood transfusion to be around 2%,
although some estimates are much higher (9,10).
Only 43% of the 191 WHO member states test
blood for HIV, hepatitis C and B viruses. Every
year, unsafe transfusion and injection practices are
estimated to account for 8-16 million Hepatitis B
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infections, 2.3-4.7 million Hepatitis C infections
and 80,000-160,000 HIV infections (11). A large
randomized trial is therefore needed of the use of a
simple, inexpensive, widely practicable antifibri-
nolytic treatment such as tranexamic acid (aprotinin
is considerably more expensive and is a bovine
product with consequent risk of allergic reaction
and hypothetically transmission of disease), in a
wide range of trauma patients, who when they
reach hospital are thought to be at risk of major
hemorrhage that could significantly affect their
chances of survival.
The CRASH 2 trial will be a large interna-
tional, placebo controlled trial of the effects of the
early administration of the antifibrinolytic agent
tranexamic acid on death, vascular events and trans-
fusion requirements (12). The trial aims to recruit
some 20,000 patients with trauma and will be one
of the largest trauma trials ever conducted. How-
ever, it will only be possible to conduct such a trial
if hundreds of healthcare professionals worldwide
work together to recruit patients to the trial in order
to make it a success.
Please contact: CRASH-2 trial Co-ordinat-
ing Centre, London School of Hygiene & Tropical
Medicine, Keppel Street, London WC1E 7H, Phone
+44 0207 958 8128, Fax: +44 0207 299 4663,
Ian.roberts@lshtm.ac.uk
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